Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.

Jiménez-Mausbach M et al.

NCBI PubMed Central · Papers · License: Open Access

machine learning systems

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 440727
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.